Education
About Us
Working with TipRanks
Follow Us
Minerva Neurosciences (NERV)
NASDAQ:NERV
NERV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.15 - $3.00
Previous CloseN/A
Volume1.19K
Average Volume (3M)15.41K
Market Cap
$12.55M
Enterprise Value$55.48M
Total Cash (Recent Filing)$21.46M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)2.2
Beta1.54
Next Earnings
Nov 10, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding6,993,406
10 Day Avg. Volume4,397
30 Day Avg. Volume15,407
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap4.42
Enterprise Value/Revenue1.31K
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda9.21
Forecast
1Y Price Target
$5.00Price Target Upside177.78% Upside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Safety ProfileThe study demonstrated an acceptable safety profile of co-administration of the two medications, and no relevant PK interactions were observed between the two drugs.
Strategic PartnershipBoehringer Ingelheim owns 18% of the company after taking a stake in Minerva, so it is suspected they will support the further development of roluperidone.
Bears Say
Financial PositionThe company reported cash at $21.5M compared with the cash position at $41M previously; the company should have approximately one-year cash runway.
Regulatory ChallengesThe company's efforts to avoid needing to do another Phase 3 study appears to be counterproductive since the Agency has made it clear on the need for at least one additional study to support the safety and effectiveness of roluperidone.
Minerva Neurosciences News
NERV FAQ
What was Minerva Neurosciences’s price range in the past 12 months?
Minerva Neurosciences lowest stock price was $1.15 and its highest was $3.00 in the past 12 months.
What is Minerva Neurosciences’s market cap?
Minerva Neurosciences’s market cap is $12.55M.
When is Minerva Neurosciences’s upcoming earnings report date?
Minerva Neurosciences’s upcoming earnings report date is Nov 10, 2025 which is in 86 days.
How were Minerva Neurosciences’s earnings last quarter?
Minerva Neurosciences released its earnings results on Aug 14, 2025. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.9 by $0.47.
Is Minerva Neurosciences overvalued?
According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued.
Does Minerva Neurosciences pay dividends?
Minerva Neurosciences does not currently pay dividends.
What is Minerva Neurosciences’s EPS estimate?
Minerva Neurosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Minerva Neurosciences have?
Minerva Neurosciences has 6,993,406 shares outstanding.
What happened to Minerva Neurosciences’s price movement after its last earnings report?
Minerva Neurosciences reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.9. Following the earnings report the stock price went down -0.552%.
Which hedge fund is a major shareholder of Minerva Neurosciences?
Currently, no hedge funds are holding shares in NERV
Company Description
Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company primarily focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is engaged in creating innovative therapies for patients suffering from neuropsychiatric disorders, including schizophrenia, depression, and Parkinson's disease, with its core product candidates being roluperidone and MIN-301.
Technical Analysis
Ownership Overview
6.80%
Insiders
21.21% Mutual Funds
0.30% Other Institutional Investors
68.12% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---